Hyperinsulinism

3 trials 2 recruiting MedDRA PT
3 Registered trials
2 Recruiting
2 Unique sponsors
2 Unique IMPs
3 Commercial trials
Drug classes (ATC)
— ATC code not specified 3
Mechanism of action (INN-stem analysis)
Unknown / small molecule 2 substances
Phase III: 2 Phase II: 1

Filter these 3 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 3 trials

Phase III

2 trials
  • Rezolute Inc. Commercial
    ANTI-(INSULIN RECEPTOR) HUMAN MONOCLONAL ANTIBODY
    2023-503240-13-00 6 countries 2024 n=32 Orphan
    Ended
  • Rezolute Inc. Commercial
    ANTI-(INSULIN RECEPTOR) HUMAN MONOCLONAL ANTIBODY
    2024-515447-36-00 2 countries 2026 n=12 Orphan
    Recruiting

Phase II

1 trial
  • Hanmi Pharm. Co. Ltd. Commercial
    EFPEGERGLUCAGON
    2024-515290-98-00 1 country 2022 n=4 Orphan
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Rezolute Inc. Commercial 2 Phase III 1
Hanmi Pharm. Co. Ltd. Commercial 1 Phase II 1
New trials by year
2022
1
2024
1
2026
1
← All indication landscapes